All Articles

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

Landmark rulings in Canada & the U.S. sanction regulators for misconduct in the MyForexFunds case, raising serious questions about accountability.

Loyalty provider Valuedynamx hires Eileen Peacock to lead U.S. growth, betting on her 'connected ecosystem' strategy to redefine customer rewards.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

The bank's Q1 earnings surge to $1.25B, driven by its Canadian Western Bank takeover and strategic deals, signaling aggressive pan-Canadian expansion.

Avista posts strong utility earnings but faces hurdles from investment losses and a key customer departure, unveiling a multi-billion dollar grid plan.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

Medtech giant reveals its 'Magnificent Seven' innovations and new data, with Chief Movement Officer Arnold Schwarzenegger leading the charge at AAOS 2026.

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

Ex-Google and Salesforce leader David Keene joins Agentive as Co-Founder, betting on agentic AI to solve the costly complexity of modern B2B sales tools.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

The cold storage giant saw strong cash flow growth in 2025 despite a net loss, but its conservative 2026 forecast signals persistent industry headwinds.